Liver cancer trial adds a resistance-blocker to standard chemo – could it boost success?
NCT ID NCT07302919
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 20 times
Summary
This study tests whether adding nicardipine (a drug that blocks a cancer resistance protein) to standard chemoembolization (TACE) improves outcomes for people with liver cancer. About 152 adults with untreated liver tumors will be randomly assigned to receive either the standard TACE or TACE plus nicardipine. The main goal is to see if the combination leads to more complete tumor responses at 3 months and longer progression-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpitaux Universitaires de Genève
RECRUITINGGeneva, 1205, Switzerland
Contact
Contact
-
Kantonsspital St. Gallen
RECRUITINGSankt Gallen, 9007, Switzerland
Contact
Contact
-
University Hospital Basel
RECRUITINGBasel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
doxorubicin and nicardipine loaded into drug-eluting beads
What this could lead to
If it works, this could improve the success rate of TACE for liver cancer, potentially leading to better tumor control and longer survival without progression.
What could go wrong
This is a mid-stage trial with only 152 participants, so results may not apply to all patients. Adding nicardipine could also increase side effects without clear benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.